(Albany, US) September 28, 2026 – DelveInsight’s “Open Angle Glaucoma Pipeline Insight 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Open-Angle Glaucoma pipeline landscape. It covers the Open-Angle Glaucoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Open-Angle Glaucoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Open-Angle Glaucoma Treatment Landscape @ https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight
Key Takeaways from the Open-Angle Glaucoma Pipeline Report
DelveInsight’s Open-Angle Glaucoma pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Open-Angle Glaucoma treatment.
The companies with Open-Angle Glaucoma drug candidates in the most advanced stage, i.e., Phase III, include Huons Co., Ltd., and others.
The leading Open-Angle Glaucoma companies include Huons Co., Ltd., Qlaris Bio, Inc., ONL Therapeutics, iVIEW Therapeutics, Inc., Ocular Therapeutix, Inc., Alcon Research, Nicox Ophthalmics, Inc., Bausch & Lomb Incorporated, Glaukos Corporation, Omikron Italia S.r.l., and others.
Promising Open-Angle Glaucoma pipeline therapies include HUC3-637, QLS-111, Xelafaslatide (ONL1204), IVW-2001 (GVB-2001), OTX-TIC, AR-17043 Ophthalmic Solution, NCX 470, BL1107, GLK-311, WB007, Citicoline, and others.
Gain in-depth knowledge of key Open-Angle Glaucoma clinical trials, emerging drugs, and market opportunities @ Open-Angle Glaucoma Clinical Trials Assessment
Open-Angle Glaucoma Overview
Open-angle glaucoma is a chronic, progressive, and irreversible optic neuropathy and the most common form of glaucoma. It is defined by an anatomically open anterior chamber angle and characteristic structural changes of the optic nerve head and retinal nerve fiber layer. The drainage angle between the cornea and iris remains open, but altered outflow dynamics contribute to optic nerve damage and gradual visual field loss. The disease occurs when the eye’s natural drainage system becomes partially blocked, with resistance developing within the trabecular meshwork, the spongy tissue that facilitates fluid outflow. This impaired drainage causes a gradual buildup of intraocular fluid, which raises pressure inside the eye and can damage the optic nerve.
Open-angle glaucoma can be classified into primary and secondary forms. In primary open-angle glaucoma, there is no obvious underlying cause, and the increased resistance appears to result from age-related changes in the trabecular meshwork. In secondary open-angle glaucoma, another condition, such as swelling, protein deposits, or cellular debris, directly contributes to or accelerates dysfunction of the drainage system.
Symptoms include gradual loss of peripheral vision, difficulty seeing objects at the edges of the visual field, missing letters when reading, and reduced visual contrast in low light. Most people do not notice these changes early, so the disease can progress silently and cause irreversible vision loss before detection, which makes regular comprehensive eye examinations essential.
Treatment aims to lower intraocular pressure (IOP) to prevent optic nerve damage. This is primarily achieved with eye drops such as prostaglandin analogs, beta-blockers, or carbonic anhydrase inhibitors. When medical therapy is insufficient or poorly tolerated, laser trabeculoplasty and surgical options, including trabeculectomy, glaucoma drainage devices, and minimally invasive glaucoma surgeries, are used.
Open-Angle Glaucoma Emerging Drugs Profile
HUC3-637: Huons Co., Ltd.
HUC3-637 is an investigational ophthalmic drug developed by Huons Co., Ltd. for primary open-angle glaucoma and ocular hypertension. It is a fixed-dose combination of dorzolamide, a carbonic anhydrase inhibitor, and timolol, a beta-blocker, formulated as a topical eye drop. It is designed to reduce IOP, the primary risk factor for glaucoma progression, by decreasing aqueous humor production through dual mechanisms. The drug is currently in the Phase III stage of development for Open-Angle Glaucoma.
QLS-111: Qlaris Bio, Inc.
QLS-111 is a novel formulation built on an ATP-sensitive potassium (KATP) channel modulator platform. It is designed to reduce IOP by relaxing blood vessels and vascular-like tissues distal to the trabecular meshwork, which decreases distal outflow resistance and lowers episcleral venous pressure (EVP), a key factor in overall IOP regulation. Clinical studies have demonstrated sustained IOP reduction both as monotherapy and in combination with standard treatments such as latanoprost, showing additive efficacy. The drug has also shown a favorable safety and tolerability profile, with no significant hyperemia or serious adverse events reported. It is currently in the Phase II/III stage of development for Open-Angle Glaucoma.
Xelafaslatide (ONL1204): ONL Therapeutics
Xelafaslatide (ONL1204) is a first-in-class small peptide that inhibits the Fas receptor, blocking activation of the Fas pathway and the related immune signaling that leads to death of key retinal cells and vision loss. By blocking Fas activation, it prevents downstream cell death signaling and inflammatory responses, preserving photoreceptors and retinal ganglion cells. Phase 1b trials have shown it to be generally safe and well tolerated, with early evidence suggesting potential to slow disease progression, such as reducing lesion growth in geographic atrophy. The drug is currently in the Phase II stage of development for Open-Angle Glaucoma.
IVW-2001 (GVB-2001): iVIEW Therapeutics, Inc.
IVW-2001 (GVB-2001) is a first-in-class gene therapy candidate for primary open-angle glaucoma, described as the world’s first glaucoma gene therapy designed for all POAG patients without stratifying by genetic subtype. It uses an optimized self-complementary AAV vector delivered by a single intracameral injection directly to the trabecular meshwork, the anatomical core of aqueous outflow obstruction. By modulating cellular function and enhancing aqueous humor outflow, it aims to deliver rapid, durable IOP control and reduce irreversible optic nerve damage at its source. The drug is currently in the Phase I/II stage of development for Open-Angle Glaucoma.
The Open-Angle Glaucoma Pipeline Report Provides Insights Into
Detailed insights about companies developing therapies for Open-Angle Glaucoma, with aggregate therapies developed by each company.
Therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Open-Angle Glaucoma treatment.
Targeted therapeutics development by Open-Angle Glaucoma companies, with respective active and inactive (dormant or discontinued) projects.
Open-Angle Glaucoma drugs under development by stage of development, route of administration, product type, and molecule type.
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and financing details for future advancement of the Open-Angle Glaucoma market.
Uncover critical updates on therapeutic innovations and their potential impact on patients @ Open-Angle Glaucoma Unmet Needs
Open-Angle Glaucoma Companies
Huons Co., Ltd., Qlaris Bio, Inc., ONL Therapeutics, iVIEW Therapeutics, Inc., Ocular Therapeutix, Inc., Alcon Research, Nicox Ophthalmics, Inc., Bausch & Lomb Incorporated, Glaukos Corporation, Omikron Italia S.r.l., and others.
The Open-Angle Glaucoma pipeline report provides the therapeutic assessment of pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Open-Angle Glaucoma products have been categorized under various Molecule types such as:
Oligonucleotide
Peptide
Small molecule
Transform your understanding of the Open-Angle Glaucoma Pipeline! @ Open-Angle Glaucoma Market Drivers and Barriers, and Future Perspectives
Scope of the Open-Angle Glaucoma Pipeline Report
Coverage: Global
Open-Angle Glaucoma Companies: Huons Co., Ltd., Qlaris Bio, Inc., ONL Therapeutics, iVIEW Therapeutics, Inc., Ocular Therapeutix, Inc., Alcon Research, Nicox Ophthalmics, Inc., Bausch & Lomb Incorporated, Glaukos Corporation, Omikron Italia S.r.l., and others.
Open-Angle Glaucoma Pipeline Therapies: HUC3-637, QLS-111, Xelafaslatide (ONL1204), IVW-2001 (GVB-2001), OTX-TIC, AR-17043 Ophthalmic Solution, NCX 470, BL1107, GLK-311, WB007, Citicoline, and others.
Open-Angle Glaucoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Open-Angle Glaucoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Access the Full Open-Angle Glaucoma Pipeline Analysis Today! @ Open-Angle Glaucoma Drugs and Companies
Table of Contents
Introduction
Executive Summary
Open-Angle Glaucoma: Overview
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Open-Angle Glaucoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Open-Angle Glaucoma Companies’ Collaborations, Licensing, Acquisition – Deal Value Trends
Open-Angle Glaucoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I/II)
Preclinical and Discovery Stage Products
Inactive Products
Open-Angle Glaucoma Key Companies
Open-Angle Glaucoma Key Products
Open-Angle Glaucoma – Unmet Needs
Open-Angle Glaucoma – Market Drivers and Barriers
Open-Angle Glaucoma – Future Perspectives and Conclusion
Open-Angle Glaucoma Analyst Views
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight
